Page 22 - சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Singapore OKs Arcturus Vaccine Trial

Arcturus Therapeutics announced on Dec. 28 that it received approval from the Singapore Health Sciences Authority to proceed with a Phase 2 clinical study of its vaccine candidate ARCT-021, also known as LUNAR-COV19. Arcturus (Nasdaq: ARCT) hopes the compound will prove effective as a vaccine against SARS-CoV-2, the virus that causes COVID-19. The new study will build upon favorable Phase 1/2 study results, as well as supportive preclinical data, Arcturus said in the announcement. Arcturus specializes in messenger RNA medicines. “We are pleased to advance ARCT-021 into a Phase 2 study based upon our promising Phase 1/2 data, which continues to support the potential for Arcturus’ STARR self-replicating mRNA technology to provide a highly effective, and differentiated clinical profile, including a single dose regimen,” said Steve Hughes, M.D., chief development officer of Arcturus. “The Phase 2 study will enable selection of the optimal ARCT-021 vaccination regimen for Phas

Steve hughesSingapore health sciences authorityArcturus therapeuticsஸ்டீவ் ஹக்ஸ்சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம்ஆர்க்டரஸ் சிகிச்சை

Arcturus Therapeutics shares slide 37% in premarket after COVID vaccine data are deemed underwhelming

Arcturus Therapeutics shares slide 37% in premarket after COVID vaccine data are deemed underwhelming
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesStephen seedhouseRaymond jamesSingapore health sciences authorityPfizer incModerna incDrug administrationArcturus therapeutics holdings incArcturus therapeutics holdingsMarket performசான் டியாகோஒன்றுபட்டது மாநிலங்களில்ரேமஂட் ஜேம்ஸ்சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம்ஃபைசர் இன்க்

Arcturus Therapeutics Receives Approval from Health Sciences Authority to Proceed with Phase 2 Study of Vaccine Candidate

Posted on 3643 Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT)reported approval from the Singapore Health Sciences Authority to commence its Phase 2 clinical study of its vaccine candidate ARCT-021. The study will utilize its favorable phase ½ study results, including supportive preclinical data. “We are pleased to advance ARCT-021 into a Phase 2 study based upon our promising Phase 1/2 data, which continues to support the potential for Arcturus’ STARR™ self-replicating mRNA technology to provide a highly effective, and differentiated clinical profile, including a single dose regimen,” said Steve Hughes, M.D., Chief Development Officer of Arcturus. “The Phase 2 study will enable selection of the optimal ARCT-021 vaccination regimen for Phase 3 registrational studies. We look forward to obtaining interim Phase 2 data in early 2021 providing support for the anticipated initiation of a global Phase 3 stud

Eng eongSteve hughesSingapore health sciences authorityInfectious diseases programmeArcturus therapeutics holdings incArcturus therapeutics holdingsChief development officerOoi eng eongEmerging infectious diseases programmeVaccine platform scientific advisoryஸ்டீவ் ஹக்ஸ்சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம்தொற்று நோய்கள் ப்ரோக்ராம்ஆர்க்டரஸ் சிகிச்சை ஹோல்டிங்ஸ் இன்க்ஆர்க்டரஸ் சிகிச்சை ஹோல்டிங்ஸ்தலைமை வளர்ச்சி அதிகாரி

Why Analysts Lost Confidence in the Arcturus COVID-19 Vaccine

Why Analysts Lost Confidence in the Arcturus COVID-19 Vaccine Chris Lange © Provided by 24/7 Wall St. An update on its COVID-19 vaccine candidate sent Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares tumbling on Tuesday. While the company did receive approval from the Singapore Health Sciences Authority to proceed with a Phase 2 clinical study of its vaccine candidate ARCT-021, the data seemed to be underwhelming. Note that the approval is based on data from the Phase 1/2 trial that demonstrated the vaccine produced neutralizing antibodies after one dose. However, these neutralizing antibodies were at lower levels than rival vaccine candidates. Arcturus is hoping its vaccine will not require a booster shot, making it easier to administer than vaccines that require two doses.

Ed arceRaymond jamesSingapore health sciences authorityArcturus therapeutics holdings incArcturus therapeutics holdingsMarket performஎட் அர்ஸ்ரேமஂட் ஜேம்ஸ்சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம்ஆர்க்டரஸ் சிகிச்சை ஹோல்டிங்ஸ் இன்க்ஆர்க்டரஸ் சிகிச்சை ஹோல்டிங்ஸ்சந்தை செய்ய

American Realty Capital Trust, Inc (NASDAQ:ARCT), Moderna, Inc (MRNA) - Why Shares Of Coronavirus Vaccine Developer Arcturus Are Sinking

American Realty Capital Trust, Inc (NASDAQ:ARCT), Moderna, Inc (MRNA) - Why Shares Of Coronavirus Vaccine Developer Arcturus Are Sinking
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesEd arceSteven seedhouseRaymond jamesSingapore health sciences authorityPfizer incModerna incArcturus therapeutics holdings incHc wainwright coCalifornia based arcturusWeek ahead in biotechData releasesRegulatory filings to move stocksGets nod for phaseNext for arcturus